Artivion (NYSE:AORT) Stock Rating Lowered by Wall Street Zen

Artivion (NYSE:AORT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research firms also recently weighed in on AORT. Canaccord Genuity Group set a $39.00 price target on shares of Artivion in a research note on Friday, August 7th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research note on Monday, June 1st. Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Finally, Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Artivion Price Performance

Artivion stock opened at $29.22 on Friday. The business’s 50-day simple moving average is $24.28 and its 200 day simple moving average is $30.51. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -417.33 and a beta of 1.24. Artivion has a 12-month low of $19.16 and a 12-month high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, research analysts anticipate that Artivion will post 0.45 earnings per share for the current year.

Insider Activity at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares of the company’s stock, valued at $5,245,521.82. The trade was a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 6.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Artivion

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Artivion during the second quarter worth about $149,965,000. Vanguard Group Inc. grew its stake in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares in the last quarter. Morgan Stanley grew its stake in Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after purchasing an additional 18,248 shares in the last quarter. State Street Corp grew its stake in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after buying an additional 44,641 shares in the last quarter. Finally, Fred Alger Management LLC lifted its stake in Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after acquiring an additional 55,322 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.